Apremilast for psoriatic arthritis rejected by NICE

NICE had rejected the NHS use of apremilast (Otezla) alone or in combination for the treatment of active psoriatic arthritis when DMARDs are unsuitable.

NICE concluded that apremilast is clinically effective compared with no other treatment. However, when compared with TNF-alpha inhibitors, apremilast was the least clinically effective for treating psoriatic arthritis. Although some costs were saved by the use of apremilast, NICE concluded they were not sufficient to justify the health losses.

Further information

Professor Carole Longson, Director of the Health Technology Evaluation Centre at NICE, explained  "there was not enough robust evidence demonstrating that apremilast slows progression of the disease compared to TNF-alpha inhibitors."

This follows a previous rejection by NICE, for the use of apremilast in moderate to severe plaque psoriasis.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from intelog

SGLT2 inhibitors: MHRA warns of Fournier's gangrene risk

SGLT2 inhibitors: MHRA warns of Fournier's gangrene risk

Cases of necrotising fasciitis of the genitalia or...

New advice for carbimazole over malformation and pancreatitis risks

New advice for carbimazole over malformation and pancreatitis risks

Reports of congenital malformations and acute pancreatitis...

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Ophthalmic Preparations, Preservatives and Potential Sensitisers as Ingredients

Potential sensitising agents in eye drops and ointments.

Antibiotic Treatments in Adults, Summary of Regimens

Antibiotic Treatments in Adults, Summary of Regimens

Dose regimens for common bacterial infections.